Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Later this month, the Stroke Prevention Research Unit, in the Nuffield Department of Clinical Neurosciences, will receive the Queen’s Anniversary Prize for Higher Education. The unit’s founder, Professor Peter Rothwell tells us about the unit and what it means to receive such a prestigious prize.

 Extracted from Issue 6, February 2014 OxfordMedSci News.

What’s the purpose of the Stroke Prevention Research Unit (SPRU)?

Professor Peter RothwellThe Stroke Prevention Research Unit (SPRU) aims to do research that increases understanding of the causes of cerebrovascular disease and improves the prevention of stroke and vascular dementia in routine clinical practice. We focus particularly on gaining a better understanding of known risk factors and more effective use of existing treatments. Over 30 research and support staff work in the unit, running several unique cohort studies in collaboration with 100 GPs in Oxfordshire.

Why do think the unit received the Queen’s Anniversary Prize for Higher Education, the highest form of national recognition that UK higher education institutions can achieve?

Queen's Anniversary Prize logoThe unit is regarded as one of the most productive stroke research groups in the world, its researchers having published over 200 papers during the last 10 years, including 30 papers in Lancet or Lancet Neurology, and 25 mainly clinical fellows have worked towards doctorates on the unit. This award recognises the team’s dedication and commitment to conducting ground breaking research, which over the last decade has revolutionised several aspects of clinical practice in stroke prevention.

For example, our unit showed that the risk of major stroke in the first few hours and days after more minor warning events – so called transient ischaemic attacks – was much higher than previously supposed, but that urgent use of existing treatments reduced the risk of major stroke by 80%. Subsequent work showed that fluctuations in blood pressure (BP) are also powerful risk factors for stroke and other vascular events and that widely used BP-lowering drugs differ in their effects on variability. And more recently, our work on aspirin has shown that, in addition to its well-known effects in preventing vascular events, it also reduces the long-term risk of several common cancers and also has shorter-term benefits by reducing the spread of cancer around the body via the blood stream (known as metastasis), demonstrating for the first time in man that a drug can directly interfere with this process.

Additional information:

DCN logoThe Stroke Prevention Research Unit has been funded by the Wellcome Trust, Wolfson Foundation, UK Stroke Association, British Heart Foundation, Dunhill Medical Trust, National Institute of Health Research (NIHR),  Medical Research Council, and the NIHR Oxford Biomedical Research Centre. The Unit also acknowledges the associated Acute Vascular Imaging Centre, Oxford.

Oxford University has now won nine Queen's Anniversary Prizes for Higher Education, more than any other university. The previous eight prizes were awarded to: the University's Wildlife Conservation Research Unit (2011); the University's museums, libraries and archives (2009); the Oxford Dictionary of National Biography at Oxford University Press (2007); the Clinical Trial Service Unit (2005); the Refugee Studies Centre (2002), the Centre for Clinical Vaccinology & Tropical Medicine (2000); the Weatherall Institute of Molecular Medicine (1996); and Isis Innovation Ltd (1994).